Loading
A phase 1/2 trial of cyclophosphamide and aldesleukin (high-dose il-2) in triple-negative breast cancer, run by Hadassah Medical Organization, now recruiting.
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers is a phase 1/2, interventional study registered as NCT05296564 by Hadassah Medical Organization, with a registry enrolment figure of 3 participants, started 2022-04-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: CYCLOPHOSPHAMIDE and FLUDARABIN; Cyclophosphamide; HBI 0201-ESO TCRT; Aldesleukin. Conditions listed: Sarcoma, Synovial; Sarcoma,Soft Tissue; Melanoma Stage IV; Triple Negative Breast Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Bladder Urothelial Carcinoma; Neuroblastoma, Metastatic; Ovary Cancer. Sites: Israel. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aldesleukin (high-dose IL-2), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/